Search

Deals roundup Boston Sci jettisons 13.3% stake in Cyberonics for $48.6 million A Medical Device Daily Staff Report Boston Scientific (Natick, Massachusetts) reported that it has liquidated its 13.3% stake [...]

The reasons behind the decline in Cyberonics stocks are examined.

Cyberonics' cyclothymic, a device used as a treatment for epileptic seizures, shares went from 40 to 13 and back to 45 as the FDA did not back the proposal. With the approval of new data presented by Skip Cummins, chief executive to the FDA, the company is expected to reach $1billion in sales by 2010 and thereby become the industry leader in the next frontier for medical devices.

An FDA advisory panel voted to recommend that the federal agency approve the Cyberonics depression device. In Houston, a few Cyberonics insiders sold some of their stock when approval of the depression device appeared imminent.

Cyberonics is offering a crucial US Food and Drug Administration (FDA) evaluation of its implantable pacemaker meant for treating people suffering from depression. It is revealed that FDA approval could add big growth to Cyberonics' sales however its failure could lead to a decline of stocks.

Despite Wall Street's wariness about the health care industry under the upcoming Clinton administration, a Houston-based biotechnology company is headed for the stock market. Cyberonics Inc. developed and manufactures the [...]

The price appreciation potential of the shares of Cyberonics, Inc. for the years 2011-2013 is discussed. The Houston, Texas-based company engages in the manufacturing and marketing of an implantable device used in treating epilepsy and depression through vagal nerve stimulation (VNS).

The shares of Cyberonics, Inc. holds limited appreciation potential over the 2011-2013 timeframe. The Houston, Texas-based company manufactures and markets an implantable device for treating epilepsy and depression through vagal nerve stimulation.

The shares of Cyberonics Inc. have below-average appreciation potential for the 2011-2013 timeframe. The Houston, Texas-based company manufactures medical devices for treating epilepsy and depression.

The price appreciation potential of the shares of Cyberonics Inc. for the years 2010-2012 is discussed. The Houston, Texas-based company manufactures implantable devices for treatment of epilepsy and depression.

The article provides the price appreciation potential of the shares of Cyberonics Inc. for the years 2010-2012. The company offers implantable device for treating epilepsy and depression through vagal nerve stimulation.

The decision of Icahn Management LP fund to acquire stake in Cyberonics is discussed. The acquisition is attributed to the frequent increase and decrease in share prices of Cyberonics.

Cyberonics share price fell sharply following United States Senate's investigations into procedure followed by Food and Drugs Administration's device centre (CDRH) for approving the company's Vagas Nerve Stimulation therapy system.

The impact of management issues on share price of Cyberonics Inc., despite U.S. Food and Drug Adminstration's autorizatioin to market pacemakers for chronic depression, is discussed.

A comparative analysis of the company sales and financial details of Cyberonics, Inc. from 1994 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.

A comparative analysis of the sales earnings and the financial details of Cyberonics, Inc. from the year 1994-2003 are detailed. Different financial ratios according to the Value Line Publication are given.

Houston biotech company seeks to capitalize medical device for controlling epileptic seizures Cyberonics Inc., a Houston-area firm that developed an implantable medical device to control epileptic seizures, is making plans [...]